✦ LIBER ✦

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients

✍ Scribed by Holger Hinrichsen; Yves Benhamou; Heiner Wedemeyer; Markus Reiser; Roel E. Sentjens; José L. Calleja; Xavier Forns; Andreas Erhardt; Jens Crönlein; Ricardo L. Chaves; Chan-Loi Yong; Gerhard Nehmiz; Gerhard G. Steinmann

Book ID: 119758034
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 182 KB
Volume: 127
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2004.08.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiviral efficacy of NS3-serine proteas

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C

✍ Markus Reiser; Holger Hinrichsen; Yves Benhamou; Henk W. Reesink; Heiner Wedemey 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB

300 Sensitivity of NS3 serine proteases

300 Sensitivity of NS3 serine proteases from various hepatitis C virus genotypes to the antiviral compound BILN 2061

✍ Diane Thibeault; Christiane Bousquet; Rock Gingras; Lisette Lagacé; Roger Mauric 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

136 Antiviral effect of BILN 2061, a nov

136 Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1

✍ Markus Reiser; Holger Hinrichsen; Yves Benhamou; Roel Sentjens; Heiner Wedemeyer 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

294 Safety and antiviral effect of BILN

294 Safety and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, and liver cirrhosis

✍ Heiner Wedemeyer; Andreas Erhardt; Wolff Schmiegel; Holger Hinrichsen; Ricardo C 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

Antiviral activity of the hepatitis C vi

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients

✍ Frank Wagner; Robert Thompson; Constantino Kantaridis; Paul Simpson; Philip J. F 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 599 KB

More effective and better-tolerated therapies are needed for chronic hepatitis C virus (HCV) infection. Among the direct-acting anti-HCV agents in development is the nonstructural 5B protein (NS5B polymerase) non-nucleoside inhibitor filibuvir. We investigated the antiviral activity, pharmacokinetic

Efficacy of Short-Term Interferon Therap

Efficacy of Short-Term Interferon Therapy for Patients Infected with Hepatitis C Virus Genotype 2a

✍ Tabaru, Akinari; Narita, Ryoichi; Hiura, Masaaki; Abe, Shintaro; Otsuki, Makoto 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 93 KB